Key Drivers
- Strong Liquidity
- Ongoing Losses
- Equity Dilution
AIAI Summary
CLYM is a well-funded but binary clinical bet: CLYM116's compelling quarterly-dosing biomarker profile could create major upside if 2027 Phase 2 data prove kidney benefit, but until then investors face dilution, a long catalyst gap, and substantial de-rating risk if biomarker gains fail to translate into efficacy.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Ongoing Losses
- •Equity Dilution
CLYM is highly liquid and lightly leveraged but remains a speculative, dilution-funded investment due to zero revenue, persistent losses, and negative cash flow.
Price Behavior
Key Price Behavior Insights:
- •Sustained reversal
- •Critical support
- •Stalled recoveries
CLYM remains bearish over the last month, with $14.00 support critical and failure to reclaim $14.56–$15.05 keeping downside risk elevated.
Sharp rise into the 2026-08-25 peak reversed into a sustained decline
Sentiment & News
Key News Insights:
- •Durable APRIL Suppression
- •Quarterly Dosing Potential
- •Phase 2 Catalyst
Climb Bio's promising Phase 1 CLYM116 data support quarterly dosing and advance its IgA nephropathy program toward Phase 2 results in H1 2027.
Positive early data may strengthen investor confidence in Climb Bio ahead of upcoming clinical milestones
Similar Companies in Healthcare
Other companies in the same sector with AI ratings